Theravectys to initiate Phase I/II trial of anti-HIV therapeutic vaccine
Using the company’s lentiviral vector technology, the anti-HIV therapeutic vaccine induces the cellular immune system for the removal of infected cells. The double-blind, controlled, placebo study, which will
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.